TY - JOUR
T1 - Genetic complexity of autosomal dominant polycystic kidney and liver diseases
AU - Cornec-Le Gall, Emilie
AU - Torres, Vicente E.
AU - Harris, Peter C.
N1 - Funding Information:
This review was supported by the National Institute of Diabetes and Digestive and Kidney Diseases grant DK058816 and the Mayo Translational Polycystic Kidney Disease Center (DK090728). An American Society of Nephrology Foundation Kidney Research Fellowship supports E.C.L.G.
Publisher Copyright:
Copyright © 2018 by the American Society of Nephrology.
PY - 2018/1
Y1 - 2018/1
N2 - Data indicate significant phenotypic and genotypic overlap, plus a common pathogenesis, between two groups of inherited disorders, autosomal dominant polycystic kidney diseases (ADPKD), a significant cause of ESRD, and autosomal dominant polycystic liver diseases (ADPLD), which result in significant PLD with minimal PKD. Eight genes have been associated with ADPKD (PKD1 and PKD2), ADPLD (PRKCSH, SEC63, LRP5, ALG8, and SEC61B), or both (GANAB). Although genetics is only infrequently used for diagnosing these diseases and prognosing the associated outcomes, its value is beginning to be appreciated, and the genomics revolution promises more reliable and less expensive molecular diagnostic tools for these diseases. We therefore propose categorization of patients with a phenotypic and genotypic descriptor that will clarify etiology, provide prognostic information, and better describe atypical cases. In genetically defined cases, the designation would include the disease and gene names, with allelic (truncating/nontruncating) information included for PKD1. Recent data have shown that biallelic disease including at least one weak ADPKD allele is a significant cause of symptomatic, very early onset ADPKD. Including a genic (and allelic) descriptor with the disease name will provide outcome clues, guide treatment, and aid prevalence estimates.
AB - Data indicate significant phenotypic and genotypic overlap, plus a common pathogenesis, between two groups of inherited disorders, autosomal dominant polycystic kidney diseases (ADPKD), a significant cause of ESRD, and autosomal dominant polycystic liver diseases (ADPLD), which result in significant PLD with minimal PKD. Eight genes have been associated with ADPKD (PKD1 and PKD2), ADPLD (PRKCSH, SEC63, LRP5, ALG8, and SEC61B), or both (GANAB). Although genetics is only infrequently used for diagnosing these diseases and prognosing the associated outcomes, its value is beginning to be appreciated, and the genomics revolution promises more reliable and less expensive molecular diagnostic tools for these diseases. We therefore propose categorization of patients with a phenotypic and genotypic descriptor that will clarify etiology, provide prognostic information, and better describe atypical cases. In genetically defined cases, the designation would include the disease and gene names, with allelic (truncating/nontruncating) information included for PKD1. Recent data have shown that biallelic disease including at least one weak ADPKD allele is a significant cause of symptomatic, very early onset ADPKD. Including a genic (and allelic) descriptor with the disease name will provide outcome clues, guide treatment, and aid prevalence estimates.
UR - http://www.scopus.com/inward/record.url?scp=85040103744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040103744&partnerID=8YFLogxK
U2 - 10.1681/ASN.2017050483
DO - 10.1681/ASN.2017050483
M3 - Review article
C2 - 29038287
AN - SCOPUS:85040103744
VL - 29
SP - 13
EP - 23
JO - Journal of the American Society of Nephrology : JASN
JF - Journal of the American Society of Nephrology : JASN
SN - 1046-6673
IS - 1
ER -